Triamcinolone Acetonide of /mL
ApprovedSmall molecule
Triamcinolone Acetonide of /mL is one of 53 small molecule programs targeting Glaucoma. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
182 competitors in Glaucoma
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Namenda
AbbViePhase 3
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Tocopherol
MM.D. Anderson Cancer Center
Phase 3
Triamcinolone Acetonide of /mL
NNishtar Medical University
Approved
TFC-003
KKukje Pharma
Phase 3
MMC in Trabeculectomy
PPro Top & Mediking Company Limited
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNishtar Medical University